Get started
Author

Nadia Califaretti

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
2021 · D. Miles, J. Gligorov, et al. · Annals of Oncology · 736
PDF
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
2016 · Tracy L. Stockley, Amit M. Oza, et al. · Genome Medicine · 276
PDF
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
2014 · X. Pivot, J. Gligorov, et al. · Annals of Oncology · 176
Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer
2015 · S. Chia, S. Gandhi, et al. · Current Oncology · 119
PDF
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
2019 · T. Bachelot, E. Ciruelos, et al. · Annals of Oncology · 114
PDF
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
2021 · D. Miles, E. Ciruelos, et al. · Annals of Oncology · 94
PDF
Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial
2021 · Monika K Krzyzanowska, Jim A Julian, et al. · BMJ · 49
PDF
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study
2014 · Mark J. Clemons, Brandy Cochrane, et al. · Breast Cancer Research and Treatment · 45
A comprehensive metabolic evaluation reveals impaired glucose metabolism and dyslipidemia in breast cancer patients early in the disease trajectory
2013 · Kirsten E. Bell, Katie M. Di Sebastiano, et al. · Clinical Nutrition · 38
A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer
2020 · M. Clemons, D. Fergusson, et al. · Annals of Oncology · 37
Plasma amino acid profiles of breast cancer patients early in the trajectory of the disease differ from healthy comparison groups
2014 · Tyler Barnes, Kirsten Bell, et al. · Applied Physiology Nutrition and Metabolism · 28
Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT)
2019 · Bassam Basulaiman, Arif Ali Awan, et al. · Breast Cancer Research and Treatment · 25
Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia
2004 · P Mollee, V Gupta, et al. · Bone Marrow Transplantation · 16
A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer
2017 · Mohammed F. K. Ibrahim, John Hilton, et al. · Breast Cancer Research and Treatment · 12
Physician Preferences for Bone Metastasis Drug Therapy in Canada
2015 · J. Arellano, J.M. González, et al. · Current Oncology · 10
PDF
Tracheobronchial Constriction in Asthmatics Induced by Isocapnic Hyperventilation With Dry Cold Air
1996 · Gabriel Julià-Serdà, Néstor A. Molfino, et al. · CHEST Journal · 7
Abstract PR03: Molecular profiling of advanced solid tumors at Princess Margaret Cancer Centre and patient outcomes with genotype-matched clinical trials
2016 · Philippe L. Bedard, Amit Oza, et al. · Clinical Cancer Research · 6
Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial
2019 · P.H. Cottu, M. De Laurentiis, et al. · Annals of Oncology · 5
PDF
A systematic review on the management of ductal carcinoma in situ of the breast
2025 · Muriel Brackstone, Lisa Durocher-Allen, et al. · Surgical Oncology · 4
Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study
2024 · Arif Ali Awan, Deanna Saunders, et al. · Current Oncology · 4
PDF
Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369.
2013 · Mark J. Clemons, Brandy Cochrane, et al. · Journal of Clinical Oncology · 4
A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer
2025 · Catherine Doyle, Ana Elisa Lohmann, et al. · Breast Cancer Research and Treatment · 3
PDF
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer
2023 · Marina Elena Cazzaniga, Foluso Ademuyiwa, et al. · JNCI Cancer Spectrum · 3
PDF
126P A randomized controlled trial (RCT) comparing optimal local treatment with or without endocrine therapy (ET) in patients (pts) aged ≥70 with lower risk breast cancer (BC) [REaCT-70 Study]
2024 · M-F. Savard, M. Sienkiewicz, et al. · ESMO Open · 2
Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada
2025 · Katarzyna J. Jerzak, Sandeep Sehdev, et al. · Current Oncology · 1
PDF
Works count: 45
Citation count: 1,822
H-index: 13
I10-index: 15
Year
Topic
Type